This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Medulloblastoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A medulloblastoma is a tumour arising from embryonic tissue in the posterior part of the cerebellar vermis. 70% of patients present before 8 years of age and it is twice as common in boys than girls. It is the most common intracranial malignant tumour of childhood and constitutes about 20% of all intracranial tumours.

It is one of the few intracranial tumours that metastasise with spinal involvement in about 40% of newly diagnoses cases. Exfoliated malignant cells are often discernible in the CSF.

  • the last 30 years have seen significant improvements in overall survival, at around 80% for patients with average risk (children >3 years of age, less than 1.5 cm2 of residual disease in the primary site, and absence of metastatic disease) and 60%-70% for high-risk patients (those with bulky residual disease, brain stem invasion, and neuraxis metastasis) with the use of standard chemotherapy and radiotherapy (craniospinal irradiation and focal boost)

Reference:

  • Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nat Rev Clin Oncol. 2011;8:540-549
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.